While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. That said, here are three profitable companies to steer clear of and a few better alternatives.
Paychex (PAYX)
Trailing 12-Month GAAP Operating Margin: 39.2%
Once known as the go-to service for small business payroll needs, Paychex (NASDAQ:PAYX) provides payroll processing, HR services, employee benefits administration, and insurance solutions to small and medium-sized businesses.
Why Does PAYX Worry Us?
- Muted 9.4% annual revenue growth over the last five years shows its demand lagged behind its software peers
- Estimated sales growth of 5.3% for the next 12 months implies demand will slow from its two-year trend
- Operating profits increased over the last year as the company gained some leverage on its fixed costs and became more efficient
At $104.00 per share, Paychex trades at 5.4x forward price-to-sales. Read our free research report to see why you should think twice about including PAYX in your portfolio.
Procter & Gamble (PG)
Trailing 12-Month GAAP Operating Margin: 24.8%
Founded by candle maker William Procter and soap maker James Gamble, Procter & Gamble (NYSE:PG) is a consumer products behemoth whose product portfolio spans everything from facial tissues to laundry detergent to feminine care to men’s grooming.
Why Is PG Not Exciting?
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Anticipated sales growth of 2% for the next year implies demand will be shaky
- Operating margin failed to increase over the last year, indicating the company couldn’t optimize its expenses
Procter & Gamble is trading at $151.19 per share, or 21.6x forward P/E. Check out our free in-depth research report to learn more about why PG doesn’t pass our bar.
Illumina (ILMN)
Trailing 12-Month GAAP Operating Margin: 19.7%
Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions.
Why Does ILMN Give Us Pause?
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
- Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 3% annually
- Negative returns on capital show management lost money while trying to expand the business
Illumina’s stock price of $278.54 implies a valuation ratio of 46.4x forward P/E. To fully understand why you should be careful with ILMN, check out our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.